Edition:
India

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Global Select Market

6.00USD
2:29am IST
Change (% chg)

$0.15 (+2.56%)
Prev Close
$5.85
Open
$6.20
Day's High
$6.45
Day's Low
$5.95
Volume
989,817
Avg. Vol
205,980
52-wk High
$6.45
52-wk Low
$2.84

Summary

Name Age Since Current Position

Peter Greenleaf

49 2018 Independent Chairman of the Board

Scott Plesha

54 2018 President, Chief Commercial Officer

Herm Cukier

53 2018 Chief Executive Officer, Director

Terry Coelho

57 2019 Chief Financial Officer

Joseph Lockhart

2018 Senior Vice President - Operations

James Vollins

50 2018 Chief Compliance Officer, General Counsel, Corporate Secretary

Thomas Smith

58 2018 Chief Medical Officer

Frank O'Donnell

69 2018 Director

Todd Davis

58 2018 Independent Director

Kevin Kotler

48 2018 Independent Director

William Watson

68 2018 Independent Director

Biographies

Name Description

Peter Greenleaf

Mr. Peter S. Greenleaf is Independent Chairman of the Board of the Company. Mr. Peter S. Greenleaf, has served as the Chief Executive Officer of Cerecor, Inc. (NASDAQ: CERQ), an integrated biopharmaceutical company focused on pediatric healthcare, since March 2018. Mr. Greenleaf previously served as Chief Executive Officer of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a biopharmaceutical company focused on medical applications of a class of ion channel modulators, from March 2014 to February 2018, when Sucampo was sold to Mallincrodt PLC (NYSE: MNK). Prior to that, Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation, a regenerative medicine company, from June 2013 to March 2014, as President of MedImmune, Inc., an fully integrated biologics division of AstraZeneca Group and President of MedImmune Ventures, a venture capital fund within the AstraZeneca Group, a global, science-led biopharmaceutical business, from January 2010 to June 2013, and Senior Vice President, Commercial Operations of MedImmune, from 2006 to 2010. Mr. Greenleaf also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson), a biotechnology company founded with the goal of developing new diagnostic assays using monoclonal antibody technology, from 1998 to 2006, and at Boehringer Mannheim G.m.b.H. (now Roche Holdings), a diagnostics and pharmaceuticals business, from 1996 to 1998. Mr. Greenleaf has served on the board of directors of Cerecor, where he has been a member of its audit committee, since May 2017. Previously, he served on the boards of directors of Sucampo, including as Chairman, from March 2013 to February 2018, Mast Therapeutics, Inc.

Scott Plesha

Mr. Scott M. Plesha is the President, Chief Commercial Officer of the Company. He joined the company in August 2015 as our Senior Vice President, Sales, with more than 26 years of sales experience and over 18 years of sales management experience within the pharmaceutical and medical industries. Mr. Plesha assumed the additional responsibility of leading our Marketing department in December 2015. Mr. Plesha leads our Specialty Sales Force, Marketing, and Training departments. Prior to joining the company, Mr. Plesha was Senior Vice President, GI Sales Force & Training at Salix Pharmaceuticals, where since 2002 he led Salix’s top rated gastrointestinal (GI) sales forces, the sales training department as well as many other sales operations functions. During Mr. Plesha’s tenure at Salix he was responsible for launching or growing product sales as well as optimizing and expanding the sales force to accommodate the multiple companies and products that Salix acquired. Prior to joining Salix, Mr. Plesha was a Regional Sales Manager for the O’Classen Dermatologics division of Watson Pharmaceuticals, Inc. Mr. Plesha began his pharmaceutical sales career with Solvay Pharmaceuticals where he was a field as well institutional sales representative. Mr. Plesha received a Bachelor of Arts in Pre-Medical Studies from DePauw University.

Herm Cukier

Mr. Herm Cukier is the Chief Executive Officer, Director of the Company. Mr. Cukier brings extensive commercial leadership experience to BDSI as the company seeks to enhance the growth of its marketed products. He has led a multitude of biopharma businesses to high growth success around the world over the last 25 years. He was most recently a Senior Vice President at Allergan plc, where his roles included being the head of its Eye Care Division, Allergan's largest division with more than $2.5 billion in annual sales, and the Head of its Women's Healthcare Division, which was one of the fastest growing segments of Allergan under his leadership reaching peak sales of $1.2 billion. He was most recently Allergan's Head of Commercial Strategy and Innovation. Mr. Cukier was also both a member of Allergan's Commercial Leadership Team and its Operational Leadership Team throughout his tenure. Prior to joining Allergan, Cukier held a series of senior executive positions with several pharmaceutical companies. His experiences also include having been the Chief Marketing Officer and member of the Executive Committee at Organon Biosciences and starting a clinical stage biotech together with Weill Cornell Medical College where he served as CEO and member of the board of directors. Earlier in his career, Cukier held positions of increasing commercial responsibility at Bristol Myers Squibb and Pfizer. He received an MBA from the Columbia Business School and a BSE in Bioengineering from the University of Pennsylvania. Mr. Cukier will be based in BDSI's headquarters in Raleigh, North Carolina.

Terry Coelho

Ms. Terry Coelho is the Chief Financial Officer of the Company. Ms. Coelho served as Chief Financial Officer and Treasurer at Balchem Corporation. Previously, she served as Chief Operating Office for Diversey, Inc., a multi-billion dollar global private equity carve-out from Sealed Air Corporation and held senior finance positions at Diversey Care from 2014 through 2017. Ms. Coelho has also served in senior finance leadership roles at Novartis from 2007 to 2014. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts degree in both Economics and International Relations, summa cum laude, from The American University, School of International Service.

Joseph Lockhart

Mr. Joseph Lockhart is the Senior Vice President - Operations of the Company. Mr. Lockhart served as Vice President, Pharmaceutical Development and Manufacturing at Salix Pharmaceuticals, where since 2001 he established the Pharmaceutical Development and Manufacturing team and contributed to multiple NDA submissions, as well as multiple product acquisitions and launches. During Mr. Lockhart’s tenure at Salix he held positions of increasing responsibility and was responsible for managing Manufacturing, Technical Operations, Formulation Development, and Clinical Trial Material Operations. From 1986 thru 2001 Mr. Lockhart served in various pharmaceutical CMC-related roles and responsibilities at both the Manager and the Director levels of management. Mr. Lockhart received a Master of Business Administration degree from the University of North Carolina at Charlotte as well as a Bachelor of Arts degree in Chemistry from the University of North Carolina at Chapel Hill.

James Vollins

Mr. James Vollins J.D., is the Chief Compliance Officer, General Counsel, Corporate Secretary of the Company. Mr. Vollins will also serve as the Company’s Chief Compliance Officer and Corporate Secretary. Jim brings over 25 years of extensive legal experience including serving as general counsel and assistant general counsel for several successful healthcare companies and as senior external counsel covering a variety of legal matters. Mr. Vollins is well versed in the fields of securities law, corporate governance and regulatory compliance relating to the commercialization and reimbursement of pharmaceutical products in the U.S. Jim received his J.D. from Case Western Reserve University School of Law, Magna cum laude, and is a graduate of Wesleyan University.

Thomas Smith

Mr. Thomas (Tom) B. Smith M.D., is the Chief Medical Officer of the Company. Dr. Smith earned a Doctor of Medicine degree from the Indiana University School of Medicine and a Bachelor of Science degree from Purdue University. He is a member of several medical societies and organizations including the American Medical Association and the American Academy of Family Physicians. Tom will be based out of the company's headquarters in Raleigh, North Carolina.

Frank O'Donnell

Dr. Frank E. O'Donnell, Jr. MD., is the Director of the Board of the Company. Dr. O’Donnell has been our Chairman of the Board and a Director since March 29, 2002. He currently serves as Executive Chairman. Dr. O’Donnell has previously served as our President and Chief Executive Officer. In January 2005, he relinquished the title of President and in August 2005 he relinquished the title of Chief Executive Officer. For more than the last six years, Dr. O’Donnell has served as a Manager of The Hopkins Capital Group, an affiliation of limited liability companies which engage in private equity and venture capital investing in disruptive technologies in healthcare. Dr. O’Donnell is also Chairman of the Board of Directors of Hedgepath Pharmaceuticals, Inc., which is developing oncology drugs for an orphan indication. Dr. O’Donnell is qualified to serve on our board of directors because of his long history with our company and his extensive experience in managing and investing in biopharmaceutical companies. Dr. O’Donnell is a graduate of The Johns Hopkins School of Medicine and received his residency training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. Dr. O’Donnell is a former professor and Chairman of the Department of Ophthalmology, St. Louis University School of Medicine. He is a trustee of St. Louis University.

Todd Davis

Mr. Todd C. Davis is Independent Director of the Company. Mr. Davis is the Founder and Managing Partner of RoyaltyRx Capital, a special opportunities investment firm. From 2006 until 2018, Mr. Davis was a Founder and Managing Partner of Cowen/HealthCare Royalty Partners, a global healthcare investment firm. He has almost thirty years of experience in both operations and investing in the biopharmaceutical and life science industries. Mr. Davis has been involved in over $3 billion in healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the Royalty Management Committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories, where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a Navy veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University.

Kevin Kotler

Mr. Kevin Kotler is an Independent Director of the Company. Kevin Kotler, has over 25 years of experience as an investor and analyst following the healthcare industry. He is the founder and Managing Member of Broadfin Capital, which is the investment advisor for Broadfin Healthcare, a healthcare focused investment fund which he launched in 2005. Mr. Kotler has served as a Director of Novelion Therapeutics, Inc. since November 2016 and has served as a director of InnerSpace Neuro Solutions, Inc., a privately-held medical device company since 2014. Mr. Kotler earned a B.S. in economics from the Wharton School at the University of Pennsylvania in 1993. The Board believes Mr. Kotler is qualified to serve on the Company’s Board due to his experience in managing biotechnology investments.

William Watson

Mr. William Mark Watson CPA is an Independent Director of the Company. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its predecessor, most recently as Central Florida Marketplace Leader. Among other industries, he has a particular expertise in the health and life sciences sector, having played a significant role in the development of Deloitte’s audit approach for health and life sciences companies and leading its national healthcare regulatory and compliance practice. He has served as lead audit partner and advisory partner on the accounts of many public companies ranging from middle market firms to Fortune 500 enterprises. Mr. Watson is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants. Mr. Watson is a member of the Board of Directors of Sykes Enterprises, Inc. (NASDAQ: SYKE). He is also Chairman of the Board of Directors and Chairman of the Audit Committee of Hedgepath Pharmaceuticals, Inc. (OTCQX:HPPI). He received his undergraduate degree in Accounting from Marquette University.

Basic Compensation